Organon & Co. Interest Expense
Organon & Co. (OGN) reported Interest Expense of $108.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2026-07-31
- Organon & Co. interest expense for the quarter ending 2026-06-30 was $108.00M, a 17.56% decline year-over-year.
- Organon & Co. interest expense for the quarter ending 2026-03-31 was $111.00M, a 10.48% decline year-over-year.
- Organon & Co. interest expense for the quarter ending 2025-12-31 was $121.00M, a 8.33% decline year-over-year.
- Organon & Co. interest expense for the quarter ending 2025-09-30 was $128.00M, a 1.59% increase year-over-year.
- Organon & Co. interest expense for fiscal 2025 was $504.00M, a 3.08% decline from fiscal 2024.
- Organon & Co. interest expense for fiscal 2024 was $520.00M, a 1.33% decline from fiscal 2023.
- Organon & Co. interest expense for fiscal 2023 was $527.00M, a 24.88% increase from fiscal 2022.
- Organon & Co. interest expense for fiscal 2022 was $422.00M, a 63.57% increase from fiscal 2021.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $108.00M 10-Q · filed 2026-07-31 | $219.00M 10-Q · filed 2026-07-31 | $340.00M derived: sum of 3 quarters · filed 2026-07-31 | $468.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | $111.00M 10-Q · filed 2026-05-04 | $232.00M derived: sum of 2 quarters · filed 2026-05-04 | $360.00M derived: sum of 3 quarters · filed 2026-05-04 | $491.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | $121.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $249.00M derived: sum of 2 quarters · filed 2026-02-24 | $380.00M derived: sum of 3 quarters · filed 2026-07-31 | $504.00M 10-K · filed 2026-02-24 |
| 2025-09-30 | $128.00M 10-Q · filed 2025-11-10 | $259.00M derived: sum of 2 quarters · filed 2026-07-31 | $383.00M 10-Q · filed 2025-11-10 | $515.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | $131.00M 10-Q · filed 2026-07-31 | $255.00M 10-Q · filed 2026-07-31 | $387.00M derived: sum of 3 quarters · filed 2026-07-31 | $513.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | $124.00M 10-Q · filed 2026-05-04 | $256.00M derived: sum of 2 quarters · filed 2026-05-04 | $382.00M derived: sum of 3 quarters · filed 2026-05-04 | $513.00M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $132.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $258.00M derived: sum of 2 quarters · filed 2026-02-24 | $389.00M derived: sum of 3 quarters · filed 2026-02-24 | $520.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $126.00M 10-Q · filed 2025-11-10 | $257.00M derived: sum of 2 quarters · filed 2025-11-10 | $388.00M 10-Q · filed 2025-11-10 | $517.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $131.00M 10-Q · filed 2025-08-06 | $262.00M 10-Q · filed 2025-08-06 | $391.00M derived: sum of 3 quarters · filed 2026-02-24 | $525.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $131.00M 10-Q · filed 2025-05-02 | $260.00M derived: sum of 2 quarters · filed 2026-02-24 | $394.00M derived: sum of 3 quarters · filed 2026-02-24 | $526.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $129.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $263.00M derived: sum of 2 quarters · filed 2026-02-24 | $395.00M derived: sum of 3 quarters · filed 2026-02-24 | $527.00M 10-K · filed 2026-02-24 |
| 2023-09-30 | $134.00M 10-Q · filed 2024-11-01 | $266.00M derived: sum of 2 quarters · filed 2024-11-01 | $398.00M 10-Q · filed 2024-11-01 | $517.00M derived: sum of 4 quarters · filed 2025-11-10 |
| 2023-06-30 | $132.00M 10-Q · filed 2024-08-07 | $264.00M 10-Q · filed 2024-08-07 | $383.00M derived: sum of 3 quarters · filed 2025-11-10 | $491.00M derived: sum of 4 quarters · filed 2025-11-10 |
| 2023-03-31 | $132.00M 10-Q · filed 2024-05-03 | $251.00M derived: sum of 2 quarters · filed 2025-11-10 | $359.00M derived: sum of 3 quarters · filed 2025-11-10 | $457.00M derived: sum of 4 quarters · filed 2025-11-10 |
| 2022-12-31 | $119.00M derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-11-10 | $227.00M derived: sum of 2 quarters · filed 2025-11-10 | $325.00M derived: sum of 3 quarters · filed 2025-11-10 | $422.00M 10-K/A · filed 2025-11-10 |
| 2022-09-30 | $108.00M 10-Q · filed 2023-11-03 | $206.00M derived: sum of 2 quarters · filed 2023-11-03 | $303.00M 10-Q · filed 2023-11-03 | $401.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $98.00M 10-Q · filed 2023-08-09 | $195.00M 10-Q · filed 2023-08-09 | $293.00M derived: sum of 3 quarters · filed 2024-02-26 | $391.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $97.00M 10-Q · filed 2023-05-05 | $195.00M derived: sum of 2 quarters · filed 2024-02-26 | $293.00M derived: sum of 3 quarters · filed 2024-02-26 | $355.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $98.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $196.00M derived: sum of 2 quarters · filed 2024-02-26 | $258.00M derived: sum of 3 quarters · filed 2024-02-26 | $258.00M 10-K · filed 2024-02-26 |
| 2021-09-30 | $98.00M 10-Q · filed 2022-11-04 | $160.00M derived: sum of 2 quarters · filed 2022-11-04 | $160.00M 10-Q · filed 2022-11-04 | $160.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $62.00M 10-Q · filed 2022-08-05 | $62.00M 10-Q · filed 2022-08-05 | $62.00M derived: sum of 3 quarters · filed 2023-02-27 | $62.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-06 | $0.00 derived: sum of 2 quarters · filed 2023-02-27 | $0.00 derived: sum of 3 quarters · filed 2023-02-27 | $0.00 derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $0.00 derived: sum of 2 quarters · filed 2023-02-27 | $0.00 derived: sum of 3 quarters · filed 2023-02-27 | $0.00 10-K · filed 2023-02-27 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-12 | $0.00 derived: sum of 2 quarters · filed 2021-11-12 | $0.00 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-16 | $0.00 10-Q · filed 2021-08-16 | ||
| 2019-12-31 | $0.00 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |